Intrathecal Injections of Autologous Mesenchymal Stem Cell-Derived Neural Progenitors in Patients with Progressive Multiple Sclerosis: Results from Phase I/II Trials

Violaine K. Harris, Ph.D., James Stark, M.D., Sophia Yang, B.A., Madison Clague, B.A., and Saud A. Sadiq, MD Presented at the International Society for Stem Cell Research (ISSCR) 2019 Annual Meeting in Los Angeles, CA.

MSC-NPs are an autologous bone marrow-derived population of cells currently under investigation as a novel MS treatment targeting CNS repair. Preclinical evidence suggests that MSC-NPs function through immunoregulatory/trophic mechanisms. The open-label phase I clinical trial in 20 patients with progressive MS demonstrated safety and tolerability of the treatment, and was associated with functional neurological improvement, particularly in ambulatory patients. Whether or not these improvements are sustained and quantifiable against a placebo control remains unknown. The objective of this study is to evaluate therapeutic efficacy of repeated dosing of intrathecal mesenchymal stem cell-derived neural progenitor (IT-MSC-NP) treatment in patients with progressive MS. Bone marrow MSCs were isolated, expanded, and cultured with neural progenitor media to generate MSC-NPs. In the phase I trial, IT-MSC-NPs were injected with 3 doses of up to 10 million cells every 3 months with follow-up EDSS assessments performed 12 and 30 months following the start of the treatment. The phase II trial is a double-blind, placebo-controlled, randomized crossover study in 50 patients with progressive MS, consisting of 6 doses of IT-MSC-NPs every 2 months. Eight of the 20 subjects in the phase I trial showed EDSS improvements (range 0.5 to 3.5 point improvement) after 12 months. The 30 month follow-up in 18 out of 20 subjects demonstrated that 7 subjects (39%) showed continued sustained improvement in EDSS. One subject who had previously demonstrated 1.0 improvement, demonstrated slight worsening in year 2. In the remaining subjects, 33% had continued stable EDSS, and 22% showed continued disease progression. These results suggest that additional treatments may be required to sustain the full effect of IT-MSC-NP treatment. A phase II trial is underway to investigate the safety and efficacy of 6 separate IT-MSC-NP treatments compared to a placebo IT-saline control. IT-MSC-NP therapy is a promising regenerative therapy for progressive MS.

Abstract Date

July 2, 2019

Abstracts archive

Pages

Tisch MS Research Center of New York

521 West 57th Street
4th Floor
New York, NY 10019
(646) 557-3900

 

Support Tisch MS

Support Tisch MS and our innovative research leading to treatments that improve the lives of patients.